Bio-Rad Laboratories Inc. (BIO) Tops Q2 EPS by 50c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts BIO Hot Sheet
Price: $369.95 +1.77%
Revenue Growth %: -0.5%
Financial Fact:
Net income per share diluted attributable to Bio-Rad: 0.61
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -0.5%
Financial Fact:
Net income per share diluted attributable to Bio-Rad: 0.61
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Bio-Rad Laboratories Inc. (NYSE: BIO) reported Q2 EPS of $1.69, $0.50 better than the analyst estimate of $1.19. Revenue for the quarter came in at $510.4 million versus the consensus estimate of $526.16 million.
For earnings history and earnings-related data on Bio-Rad Laboratories Inc. (BIO) click here.
For earnings history and earnings-related data on Bio-Rad Laboratories Inc. (BIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- JPMorgan Upgrades Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) to Neutral
- Coforge Ltd (COFORGE:IN) PT Raised to INR2,460 at UBS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
